Almost everything favourable belongs to magnesium itself, not the malate. Higher intake tracks with less stroke and heart failure and lower death rates; supplementation modestly lowers blood pressure and blood sugar, mostly in those short of the mineral. The malate portion’s energy and muscle claims remain untested in people. Loose stools limit dose; impaired kidneys are the real danger. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Red blood cell magnesium | 6.0-6.5 mg/dL | Reflects tissue magnesium stores |
| Serum magnesium | 2.0-2.3 mg/dL | Detects depletion and excess alike |
| eGFR (estimated glomerular filtration rate) | Above 90 mL/min/1.73 m² | Whether a magnesium load clears safely |
| Serum potassium | 4.0-4.5 mEq/L | Low magnesium drives potassium wasting |
| Serum calcium (albumin-corrected) | 9.2-9.8 mg/dL | Severe magnesium depletion lowers calcium |
| 25-hydroxyvitamin D | 40-60 ng/mL | Repletion raises magnesium demand |
| HbA1c (glycated haemoglobin) | Below 5.4% | Tracks the glucose benefit |
| hs-CRP | Below 1.0 mg/L | Tracks the inflammatory marker |
| Home blood pressure | Below 120/80 mm Hg | Best-evidenced objective endpoint |
Cadence: Baseline, 12 weeks, then every 6-12 months; within 4 weeks of a dose increase, new kidney-affecting drug or declining kidney function.